Biotechnology Assets S.A. | Small-cap | Healthcare
€0.36
-1.93%
| Biotechnology Assets Stock Comparison:
Biotechnology Assets vs Pharma Mar S.ABiotechnology Assets vs Atrys Health S.ABiotechnology Assets vs Vytrus Biotech S.ABiotechnology Assets vs Oryzon Genomics S.ABiotechnology Assets vs Grifols, S.ABiotechnology Assets vs IBEX 35 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 14.8M
Total Liabilities 8.2M
Shareholders Equity 6.6M
Debt to Equity 1.24

Cash Flow Metrics

Revenue & Profitability Trend

Biotechnology Assets Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i2.5M3.6M2.6M3.1M2.5M
Cost of Goods Sold i-138.4K107.0K-20.9K49.8K-196.8K
Gross Profit i2.7M3.5M2.6M3.0M2.7M
Gross Margin % i105.5%97.0%100.8%98.4%107.8%
Operating Expenses
Research & Development i0018.2K20.3K47.5K
Selling, General & Administrative i465.3K496.9K619.5K952.8K387.2K
Other Operating Expenses i327.4K330.9K272.5K214.1K251.3K
Total Operating Expenses i792.7K827.8K910.2K1.2M686.0K
Operating Income i-2.2M3.0M-1.7M-1.5M-1.2M
Operating Margin % i-88.1%82.7%-65.3%-49.8%-46.6%
Non-Operating Items
Interest Income i1.4K2.3K1614.2K85
Interest Expense i181.3K311.0K345.5K854.7K333.4K
Other Non-Operating Income-----
Pre-tax Income i-3.1M2.3M-2.0M-2.9M-1.6M
Income Tax i-139.1K748.6K-99.0K103.5K150.3K
Effective Tax Rate % i0.0%32.2%0.0%0.0%0.0%
Net Income i-2.9M1.6M-1.9M-3.0M-8.6M
Net Margin % i-116.0%43.7%-74.4%-97.7%-340.9%
Key Metrics
EBITDA i-110.1K5.2M450.4K21.9K993.1K
EPS (Basic) i€-0.04€0.03€-0.04€-0.07€-0.22
EPS (Diluted) i€-0.04€0.03€-0.04€-0.07€-0.22
Basic Shares Outstanding i6528761057725603542011634561411139191215
Diluted Shares Outstanding i6528761057725603542011634561411139191215

Income Statement Trend

Biotechnology Assets Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i143.8K311.1K664.3K1.7M556.0K
Short-term Investments i46.6K44.9K86.7K24.8K25.5K
Accounts Receivable i3.3M3.1M2.1M2.6M2.7M
Inventory i--0018.1K
Other Current Assets0-0-0
Total Current Assets i3.7M3.8M3.1M4.4M3.4M
Non-Current Assets
Property, Plant & Equipment i481.2K479.1K478.1K394.1K393.6K
Goodwill i7.1M9.2M11.9M12.6M14.5M
Intangible Assets i4.2M5.0M6.4M5.8M6.4M
Long-term Investments448.3K445.2K245.8K244.4K243.2K
Other Non-Current Assets---0-
Total Non-Current Assets i11.1M12.8M15.4M15.5M16.8M
Total Assets i14.8M16.6M18.5M19.9M20.2M
Liabilities
Current Liabilities
Accounts Payable i197.3K311.2K395.9K302.6K388.3K
Short-term Debt i2.7M2.0M2.0M481.0K959.7K
Current Portion of Long-term Debt-----
Other Current Liabilities--08390
Total Current Liabilities i4.5M3.6M3.5M3.6M9.5M
Non-Current Liabilities
Long-term Debt i2.4M5.2M9.8M3.1M2.2M
Deferred Tax Liabilities i439.6K511.5K499.4K602.6K671.7K
Other Non-Current Liabilities0-0-0
Total Non-Current Liabilities i3.6M6.5M11.1M12.0M6.9M
Total Liabilities i8.2M10.1M14.6M15.5M16.4M
Equity
Common Stock i3.3M2.9M2.7M2.3M2.0M
Retained Earnings i-23.6M-20.7M-22.2M-19.9M-16.8M
Treasury Stock i27.5K48.0K34.1K102.6K116.5K
Other Equity-----
Total Shareholders Equity i6.6M6.5M3.9M4.3M3.8M
Key Metrics
Total Debt i5.1M7.1M11.7M3.6M3.2M
Working Capital i-851.3K147.8K-413.4K851.2K-6.1M

Balance Sheet Composition

Biotechnology Assets Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-3.1M2.3M-2.0M-3.0M-8.5M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-486.5K-542.1K369.2K-496.3K22.5M
Operating Cash Flow i-3.0M-2.9M-1.5M-2.9M15.4M
Investing Activities
Capital Expenditures i-13.8K-69.6K-127.6K-17.0K39.4M
Acquisitions i---0-608.7K
Investment Purchases i-----
Investment Sales i--00998.9K
Investing Cash Flow i-13.8K-69.6K-127.6K-17.0K39.8M
Financing Activities
Share Repurchases i-120.5K-76.1K-81.0K0-15.0K
Dividends Paid i-----
Debt Issuance i1.6M594.7K590.0K795.1K0
Debt Repayment i-1.7M-721.5K-813.3K-555.0K-57.9M
Financing Cash Flow i637.8K-61.0K1.1M3.3M-57.9M
Free Cash Flow i-794.6K-278.2K-2.1M-2.2M8.4M
Net Change in Cash i-2.4M-3.1M-440.8K329.2K-2.7M

Cash Flow Trend

Biotechnology Assets Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 10.77
Price to Book 3.56
Price to Sales 8.12
PEG Ratio -0.04

Profitability Ratios

Profit Margin -98.39%
Operating Margin -38.88%
Return on Equity -44.40%
Return on Assets -9.11%

Financial Health

Current Ratio 0.81
Debt to Equity 31.56
Beta 1.65

Per Share Data

EPS (TTM) €-0.04
Book Value per Share €0.10
Revenue per Share €0.05

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
bst24.1M10.773.56-44.40%-98.39%31.56
Pharma Mar S.A 1.4B33.616.8321.94%22.20%25.51
Atrys Health S.A 214.1M-6.690.85-11.73%-14.57%100.85
Vytrus Biotech S.A 41.4M39.295.6816.23%16.76%24.31
Oryzon Genomics S.A 203.9M-44.561.96-4.20%-58.55%15.22
Grifols, S.A 7.8B29.191.694.99%4.00%126.87

Financial data is updated regularly. All figures are in the company's reporting currency.